Long-term outcomes in individuals with prolonged PR interval (>200 ms; first-degree atrioventricular block) compared with individuals with normal PR interval in the Framingham Heart Study.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Primary indications (in thousands) for pacemaker placement between 1990 and 2002 from the National Hospital Discharge Survey.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Incidence rate of paroxysmal supraventricular tachycardia per 100,000 person-years by age and sex.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Current and future US prevalence projections for atrial fibrillation (AF).
Atrial fibrillation incidence by race.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Lifetime cumulative risk for atrial fibrillation (AF) at different ages (through age 94 years) by sex.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Population attributable fraction of major risk factors for atrial fibrillation in the Atherosclerosis Risk in Communities study.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360

Copyright © American Heart Association, Inc. All rights reserved.
Cumulative incidence of events in the 5 years after diagnosis of incident atrial fibrillation (AF) in Medicare patients.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Atrial fibrillation (AF) cost estimates, where AF is the primary diagnosis in inpatient and outpatient encounters.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360
Global age-adjusted atrial fibrillation prevalence rates (per 100 000 population) in the 2010 Global Burden of Disease Study.

Dariush Mozaffarian et al. Circulation. 2016;133:e38-e360